[1] 周莹,高劲松,胡静,等.围产儿死亡151例分析[J].生殖医学杂志,2018,27(4):299-304. [2] 孙丽雅,邢清和,贺林.中国出生缺陷遗传学研究的回顾与展望[J].遗传,2018,40(10):800-813. [3] 杨璇,陈富臻,洪强.501例新生儿溶血病筛查结果分析[J].中国实验血液学杂志. 2019.27(01):192-196. [4] LI SI,HE ZHIMING,LUO YANMIN,et al.Distribution of maternal red cell antibodies and the risk of severe alloimmune haemolytic disease of the foetus in a Chinese population:a cohort study on prenatal management.[J]. BMC Pregnancy Childbirth,2020, 20(1):539. [5] 中国输血协会免疫学液学专业委员会.胎儿新生儿溶血病实验室检测专家共识[J].临床输血与检验,2021,23(1):20-23,28. [6] 杨世明,张勇萍,安宁,等.新生儿溶血病红细胞血型免疫性抗体的特异性分析[J].细胞与分子免疫学杂志, 2011, 27(10):1130-1131. [7] 杜肖刚,王丽荣,段燕军.未孕女性IgG类抗A(B)抗体效价测定分析[J].长治医学院学报,2016.30(2):137-139. [8] 邵肖梅,叶鸿瑁,丘小汕主编.实用新生儿学[M].第4版.北京:人民卫生出版社,2011. [9] WRIGHT C F,WEI Y H,HIGGINS J P,et al.Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis[J].BMC Res Notes,2012,5(1):476. [10] BRICCA P,GUINCHARD E,GUITTON Bliem C.Management of feto-maternal red cell allo-immunizations[J].Transfus Clin Biol,2011,18(2): 269-276. [11] DE HAAS M,THURIKF F,KOELEWIJN J M,et al.Haemolytic disease of the fetus and newborn[J].Vox Sang,2015,109(2):99-113. [12] Phung Thanh-Vy,Houfflin-Debarge Véronique, Ramdane Nassima,et al.Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody[J].Transfusion, 2018,58(5):1199-1205. [13] 刘曦,范亮峰,郑皆炜,等.306例不规则抗体致新生儿溶血病回顾性研究[J].中国输血杂志,2018,31(11): 1261-1264. [14] 张勇萍,杨世明,安宁,等.母婴血型不合新生儿溶血病及其血型血清学检测的临床意义[J].细胞与分子免疫学杂志,2013.29(11):1229-1231. [15] 雷慧芬,樊凤艳,肖军,等.国内医疗机构胎儿新生儿溶血病免疫血液学检测情况分析[J].临床输血与检验,2021,23(1):33-38. [16] 肖军,郑飞天,陈柄澔,等.O型孕产妇IgG抗体效价与胎儿新生儿溶血病关系的Meta分析[J].中国输血杂志, 2020,33(9):925-928. [17] 林园. 新生儿溶血病(HDN)免疫血液学试验推荐方案[J].中国输血杂志,2012.25(2):95-100. [18] 李志强. RhD抗原阴性孕产妇血液安全管理专家共识[J].中国输血杂志. 2017,30(10):1085-1091. [19] British Committee for Standards in Haematology, Milkins C,Berryman J,et al.Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories[J].Transfus Med,2013,23(1):3-35. [20] Royal College of Obstetricians and Gynaecologists (RCOG).Green-top guideline no.65:the management of women with red cell antibodies during pregnancy[J].Obstet Gynecol,2014,16(3):224. [21] WHITE J,QURESHI H,MASSEY E,et al.Guideline for blood grouping and red cell antibody testing in pregnancy[J].Transfus Med,2016,26(4):246-263. [22] SOOTHILL P W,FINNING K,LATHAM T,et al.Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative:implementation in the NHS[J].BJOG:Int J Obstet Gy,2015,122(12):1682-1686. [23] 张嘉敏,陈和平,向东,等.单核细胞单层试验和抗体效价测定预判新生儿溶血病的比较[J].临床输血与检验,2006,8(1):17-19. [24] 严英榴,杨秀雄,主编.产前超声诊断学[M].第2版.北京:人民卫生出版社,2012. [25] NEW H V.Transfusion in neonates and older children:Principles and updates[J].Transfus Clinique et Biol,2019,26(3):195-196. [26] NEW H V,BERRYMAN J,BOLTON-MAGGS P H B,et al.Guidelines on transfusion for fetuses,neonates and older children[J].Br J Haematol,2016,175(5):784-828. [27] 丁国芳. 新生儿黄疸干预推荐方案[J].中华儿科杂志, 2001,39(3):185-187. [28] 《中华儿科杂志》编辑委员会,中华医学会儿科学分会新生儿学组.新生儿黄疸诊疗原则的专家共识[J].中华儿科杂志,2010,48(9):685-686. [29] 郭永建,马春会.英国小儿输血指南主要推荐及其启示(续1)[J].中国输血杂志,2017,30(11):1312-1320. [30] 梁洁. 茵陈蒿汤联合维生素C治疗IgG抗体高效价孕妇预防新生儿溶血病的临床观察[J].中国临床新医学,2016,9(10): 873-875. [31] BRINC D,DENOMME G A,LAZARUS A H.Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn:what can we learn from rodent models?[J].Curr Opin Hematol,2009,16(6):488-496. [32] QURESHI H,MASSEY E,KIRWAN D,et al.BCSH guideline for the use of anti-D immunoglobulin for the prevention of haemolytic disease of the fetus and newborn[J].Transfus Med,2014,24(1):8-20. [33] GORDON L G,HYLAND C A,HYETT J A,et al.Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia:a cost-effectiveness analysis[J].Prenat Diagn,2017,37(12):1245-1253. |